GA NCORP

Treatment Sites

Northside Hospital Cancer Institute

Northside Hospital Cancer Institute
Atlanta, Georgia

Northside Hospital Cancer Institute offers the best of both worlds: clinical excellence on par with academic-based programs, along with the personalized and attentive care typically associated with a community hospital. Northside, which has been offering cancer care services since 1978, is one of the largest and most respected providers of cancer care services in the Southeast.


  • The Blood & Marrow Transplant Program at Northside Hospital has ranked #1 in the United States for the third consecutive year, for having the best survival rates for matched related and unrelated donors (MUD) /allogeneic transplants.
  • More cases of breast cancer and gynecologic (cervical, ovarian and uterine) cancer are diagnosed and treated than at any other hospital in the Southeast.
  • More prostate cancer treatments are performed at Northside than at any other hospital in Atlanta
  • Fully accredited by the American College of Surgeons Commission on Cancer.
    Northside also received an Outstanding Achievement Award.

Our renowned program also consists of palliative care, cancer genetics, screenings, research, support and survivorship.

(404) 851-8000
www.northside.com

Treatment Sites


Primary Location

1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355 (p)
www.northside.com

driving directions

Clinical Trials

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type: Multiple Primaries
Study Coordinator: Stacey Brown - 404-780-7965


A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Cancer Type: Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma)

A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type: Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type: Head and Neck Cancer, Lung Cancer
Study Coordinator: Anila Lokhandwala - 404-256-4777 x9242


A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type: Lymphoma, Non-Hodgkin Lymphoma
Study Coordinator: Stacey Brown - 404-780-7965


A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type: Unknown Primary
Study Coordinator: Anila Lokhandwala - 404-256-4777 x9242


A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary
Study Coordinator: - 404-303-3355


A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Cancer Type: Hodgkin Lymphoma

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type: Lymphoma, Multiple Myeloma
Study Coordinator: Stacey Brown - 404-780-7965


A Phase I / II Study of SEL24 in Patients With Acute Myeloid Leukemia
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-780-7965


A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Cancer Type: Lymphoma

A Phase IB Study of Blinatumomab in Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) as Post-Allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance
Cancer Type: Lymphoma

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type: Breast Cancer, Unknown Primary

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL
Cancer Type: Leukemia

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Cancer Type: Unspecified

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Cancer Type: Unspecified

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I / II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4 / RTOG-3515)
Cancer Type: Lung Cancer

A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Stacey Brown - 404-780-7965


A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Cancer Type: Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Cancer Type: Ovarian Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma, Unknown Primary
Study Coordinator: - 404-303-3355


A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary
Study Coordinator: - 404-303-3355


A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Cancer Type: Unspecified

A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
Cancer Type: Symptom Management

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Cancer Moonshot Biobank Research Protocol
Cancer Type: Unspecified

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer
Study Coordinator: - 404-303-3355


Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)
Cancer Type: Lymphoma

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: - 404-303-3355


Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for Patients 60-75 Years of Age With Secondary AML
Cancer Type: Unspecified

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Cancer Type: Unspecified

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Cancer Type: Unspecified

Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease
Cancer Type: Symptom Management

Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer
Study Coordinator: - 404-303-3355


Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer, Unknown Primary
Study Coordinator: - 404-303-3355


Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Cancer Type: Unspecified

Protocol For A Research Database For Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries
Cancer Type: Hematologic Malignancies
Study Coordinator: Stacey Brown - 404-780-7965


Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Cancer Type: Melanoma

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Renee Gaiter - 404-303-3355


Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease
Cancer Type: Unspecified
Study Coordinator: Stacey Brown - 404-780-7965


The Impact of Hematopoietic Stem Cell Transplantation on Primary Caregiver Level of Burden and Distress
Cancer Type: Quality of Life

The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)
Study Coordinator: - 404-303-3355


Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Cancer Type: Unspecified
Study Coordinator: - 404-303-3355